TY - JOUR T1 - Hepatotoxicity from pyrazinamide based anti-tuberculous therapy: protective effect from isoniazid and HIV infection? JF - Thorax JO - Thorax SP - 210 LP - 210 DO - 10.1136/thx.2004.la0139 VL - 60 IS - 3 AU - A E Boyd Y1 - 2005/03/01 UR - http://thorax.bmj.com/content/60/3/210.abstract N2 - ▴ Van Hest R, Baars H, Kik S, et al. Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment. Clin Infect Dis2004;39:488–96OpenUrlAbstract/FREE Full Text ▴ Gordin FM, Cohn DL, Matts JP, et al. Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons? Clin Infect Dis2004;39:561–5OpenUrlAbstract/FREE Full Text In 1999 the American Thoracic Society (ATS), the Centers for Disease Control and Prevention (CDC), and the Infectious Diseases Society of America (IDSA) endorsed a 2 month daily regimen of rifampin and pyrazinamide (2RZ) for the treatment of latent tuberculosis (TB) infection. This recommendation followed a prospective randomised trial in HIV infected persons showing that 2RZ had similar efficacy and safety to a 12 month regimen of daily … ER -